ResMed’s Q1 2027: A Wakeful Quarter as EPS Rises and the Sleep Economy Advances
ResMed Inc. (NYSE: RMD, ASX: RMD) kicked off fiscal year 2027 with a solid first quarter, delivering a revenue rise and meaningful earnings per share progress. The company reported Q1 revenue of approximately $1.4 billion, up 6% year over year, with GAAP diluted EPS at $2.92—up 23%—and non-GAAP diluted EPS at $2.91, up 14%. In parallel, ResMed returned more than $1 billion to shareholders via share repurchases and dividends, underscoring a capital-light, cash-generative profile as it refines its portfolio. RMD also highlighted strategic portfolio moves—completing the MatrixCare divestiture and advancing product and partner initiatives designed to broaden the company’s reach in home-based sleep and breathing health.
Key numbers and execution
- Revenue: $1.4 billion, +6% year over year (core constant currency growth cited in the release).
- EPS (GAAP): $2.92, up 23% from a year ago.
- EPS (non-GAAP): $2.91, up 14% year over year.
- Shareholder returns: Returned >$1.0 billion through buybacks and dividends in Q1.
- Divestiture: Closed the MatrixCare transaction, narrowing the strategic focus.
The release frames these results as evidence of continued demand for sleep and breathing health solutions, with a notable emphasis on core constant currency growth and margin discipline. While the document does not publish a formal EPS consensus or a full-year revenue forecast, the quarterly trajectory and the robust cash generation suggest management is steering toward a sustainable, higher-quality earnings profile even as it reshapes the portfolio.
Strategic moves and highlights
- MatrixCare divestiture: The company closed the previously announced sale, signaling a pivot toward its core sleep technology and home-delivery model rather than institutional care software assets.
- Product and partnerships: Announced U.S. launch of the AirTouch F40, a new CPAP mask, reinforcing resilience in the company’s core hardware lineup.
- Collaborations: Partnered with Eight Sleep to connect its sleep insights with ResMed’s platform, expanding the digital health ecosystem and cross-industry integration.
- Public engagement: Tied communications to broader audience reach by associating with Tyler Reddick (NASCAR) after his sleep apnea diagnosis, a move designed to raise awareness of sleep disorders beyond traditional medical channels.
- Governance: Appointment of Carol Burt as Lead Director, effective November 15, 2026, signaling ongoing governance refresh amid leadership transitions.
The combination of a completed divestiture, a strategic product launch, and diversification through partnerships points to a deliberate shift toward a more streamlined, consumer- and home-centric growth engine. The press release emphasizes execution in a world where EPS and revenue quality often matters more than sheer top-line expansion.
Leadership view and the road ahead
Company leadership framed the quarter as a strong start to fiscal 2027, citing demand for sleep and breathing health solutions and ongoing execution across the business. Chairman and CEO Mick Farrell noted that year-over-year improvements in core metrics were driven by a combination of revenue growth, a higher non-GAAP gross margin, and a meaningful increase in non-GAAP earnings per share. The emphasis on free cash flow and the financing proceeds from MatrixCare helped the company invest in innovation while delivering returns to shareholders.
Looking forward, ResMed envisions expanding its digital health ecosystem and extending its reach to more people who can benefit from at-home care. The company highlighted a continued push to connect patients with life-saving treatment in their own homes, a strategy that aligns with broader industry trends toward remote monitoring, consumer health tech partnerships, and value-based care models.
What this might portend for peers and competitors
ResMed’s quarter is a case study in how a medtech company can pair strong quarterly earnings with portfolio discipline. The MatrixCare divestiture narrows risk and capital allocation complexity, a pattern that peers might emulate if their businesses include non-core units with limited scaling potential. The AirTouch F40 launch and the Eight Sleep collaboration illustrate a broader industry tilt toward consumer-grade, at-home health devices that feed into a larger sleep-diagnostics and treatment ecosystem.
For sector peers, the message is twofold: maintain credible margin expansion while courting partnerships that blend hardware with data-driven insights. In markets where EPS and margins have become the currency of confidence, a disciplined approach to capital deployment—evidenced by >$1 billion in shareholder returns—could become a differentiator in a crowded field of sleep and respiratory health players.
Operational notes worth watching
The press release notes a webcast of the conference call at 4:30 p.m. ET, a reminder that the narrative may evolve with management commentary. The company also anchors its disclosures in GAAP and non-GAAP metrics, a practice that invites investors to scrutinize the adjustments behind the EPS figures and the gamma between reported and underlying performance.
The Q1 results incorporate a mix of core product momentum and strategic portfolio actions, a combination that can influence the earnings surprise and the interpretation of subsequent quarterly prints. Without a published revenue forecast for the year in this excerpt, investors will likely weigh guidance when it becomes available and monitor how the company translates its at-home care push into sustained growth.
Bottom line
ResMed’s first quarter of fiscal 2027 presents a disciplined earnings story: growth in revenue and EPS, substantial capital returns, and a strategy-tuned portfolio that emphasizes core sleep and breathing health activities. The MatrixCare divestiture, new product launches, and health-tech partnerships signal a constructive path toward a more integrated at-home care model. For investors, the near-term question remains whether the rest of FY2027 can sustain higher EPS and cash flow in the face of evolving macro dynamics and competitive pressures. If the company can blend continued top-line momentum with the margin discipline it demonstrated in Q1, RMD may offer a reliable anchor in a sector where the narrative increasingly centers on outcomes, not just inputs.